

M components – a review of 1242 cases

A. AMEIS, MD; H.S. KO, MD; W. PRUZANSKI, MD, FRCP[C], FACP

Among 1242 patients referred for immunologic investigation 1255 M components were detected in the serum. Of these patients 50.9% had multiple myeloma, 18.1% had nonmyelomatous malignant diseases such as macroglobulinemia, lymphoma, leukemia or cancer, 4.3% had connective tissue diseases, 2.5% had primary generalized amyloidosis (PGA) and the rest had various "benign" conditions.

Whereas IgG was the commonest M component in multiple myeloma, connective tissue diseases and the other benign conditions, IgM was the commonest M component in lymphoma and leukemia; Bence Jones proteinemia was most frequently observed in PGA. The ratio of κ to λ light chains varied from 1.7:1 in IgG myeloma to 1:9 in IgD myeloma, and was 1:2.1 in PGA.

Bence Jones protein was detected in 422 (66%) of 640 urine samples tested, the prevalence ranging from more than 70% in multiple myeloma and PGA to as low as 36% in various benign conditions.

It is evident that the class and type of M components and the presence of Bence Jones proteinuria have no definite significance with regard to the diagnosis. Therefore, thorough investigation and follow-up at regular intervals are required when M components are detected.

Chez 1242 patients reçus en consultation pour examen immunologique, 1255 constituants M ont été décelés dans le sérum. De ces patients 50.9% étaient atteints de myélome multiple, 18.1% souffraient de maladies malignes

nonmyélomateuses telles que macroglobulinémie, lymphome, leucémie ou cancer, 4.3% avaient des collagénoses, 2.5% souffraient d'amyloidose primaire généralisée (APG) et les autres présentaient diverses affections "bénignes".

Alors que les IgG représentaient le principal constituant M dans les cas de myélome multiple, les collagénoses et les affections bénignes, les IgM étaient le constituant M le plus fréquent dans les lymphomes et les leucémies; la protéinémie de Bence Jones a été le plus fréquemment observée dans l'APG. Le rapport des chaînes légères κ aux chaînes λ a varié de 1.7:1 dans les myélomes à IgG à 1.9:1 dans les myélomes à IgD et a été de 1:2.1 dans l'APG.

Les protéines de Bence Jones ont été décelées dans 422 (66%) des 640 échantillons d'urine testés, la fréquence variant de plus de 70% dans les cas de myélome multiple et l'APG à moins de 36% dans diverses affections bénignes.

Il est évident que la classe et le type de constituant M et la présence de protéinurie de Bence Jones ne comportent aucune signification définitive en ce qui a trait au diagnostic. Donc, un examen approfondi et une surveillance à intervalles réguliers sont de mise lorsque des constituants M sont décelés.

Immunoglobulins (Ig) are synthesized and secreted by lymphocytes and plasma cells. In physiologic conditions they are synthesized in a harmonious balance, the proportions of the various classes (IgG, IgA, IgM, IgD and IgE) and of the two types of light chains (κ and λ) being fairly constant. Antigenic stimulation, such as infection or immunization, may cause excessive production of Ig (antibodies), which is almost invariably heterogeneous, and give rise

to polyclonal hypergammaglobulinemia. On the other hand, when a single clone proliferates abnormally, the produced immunoglobulin is homogeneous and has only one class of heavy chain and one type of light chain. Such a homogeneous (monoclonal) immunoglobulin is called an M component. It is usually seen in serum (or urine) electrophoresis as a narrow band or spike. The diagnosis should be confirmed by immunoelectrophoresis. Occasionally two or three abnormal clones of cells proliferate simultaneously or sequentially, producing two or three different M components.

Until a few years ago M components were usually considered to denote malignant processes; however, they were also found in patients with non-neoplastic diseases and in healthy individuals. Therefore, it seemed important to analyse a large series of patients with M components in relation to diagnosis of their conditions. In this paper we present such an analysis, based on data from 1242 patients with M components.

Material and methods

Between June 1967 and June 1975, 1242 serum and 640 urine samples were referred to our laboratory from hospitals in Toronto and other centres for investigation because M components were suspected. All serum underwent assay for total protein, cellulose acetate electrophoresis, immunoelectrophoresis, immunoquantitation and cryoglobulin assay, as described previously.^{1,2} Urine was concentrated, when required, up to 3000 times, by either negative pressure dialysis or concentration against 30% polyvinylpyrrolidone. Antisera against Ig, IgG, IgA, IgM, IgD and Fc and Fab fragments, and immunoquantitation plates for IgG, IgA, IgM and IgD were purchased from Hyland Laboratories, Los An-

From the University of Toronto immunoglobulin diagnostic and research centre and the department of medicine, Wellesley Hospital, Toronto

Reprint requests to: Dr. W. Pruzanski, Director, Immunoglobulin diagnostic and research centre, Wellesley Hospital, 160 Wellesley St. E., Toronto, ON M4Y 1J3

geles, California, and from Meloy Laboratories, Springfield, Virginia. Antisera against IgE, Bence Jones protein types κ and λ , and free κ and λ light chains were produced in our laboratory.

The data reported in this paper were obtained only from cases in which the presence of M components was confirmed and there was sufficient information for a clinical diagnosis.

Results

All but 3 of the 1242 patients had one or more M components in the serum, and altogether 1255 M components were found. The three other patients had Bence Jones proteinuria only. Bence Jones proteinuria was found in 422 (66%) of the 640 urine samples.

Prevalence of M components according to immunoglobulin class and light-chain type is shown in Table I. Classification of M components according to diagnosis (Table II) shows that 50.9% of patients with this abnormality had multiple myeloma and 18.1% had a nonmyelomatous malignant disease.

In malignant plasmacytic diseases (Table III) the prevalence of different classes of M components corresponded approximately to the physiologic concentration of various immunoglobulin classes in the serum, IgG myeloma being the most frequently observed disease. Among the myelomas the ratio of κ to λ light chains of M components varied, ranging from 1.7:1 in IgG myeloma to 1:9 in IgD myeloma (Table IV). The highest prevalence of Bence Jones proteinuria in multiple myeloma

was found in light-chain disease and in IgD myeloma, and the lowest in IgA(κ) myeloma.

In Waldenström's macroglobulinemia (Table V) the ratio of κ to λ light chains was 2.5:1 and 58.3% of the urine samples tested contained Bence Jones protein; 16% of the serum samples contained cryoglobulin and a similar proportion contained cold agglutinin. Among the 67 M components found in patients with lymphoma and Hodgkin's disease (Table V) 34 (50%) were of the IgM class; this proportion contrasts with the overall proportion of IgM M components in our series — 13.0% (Table I). In lymphoma the ratio of κ to λ light chains of M com-

ponents was 2.1:1. Fifty percent of the patients had a lymphocytic type of lymphoma and 20% had a histiocytic type. All patients were in stage III or IV of lymphoma and the average duration of disease when M components were detected was 29.3 months. Anemia, abnormal peripheral blood lymphocytes and lymphomatous involvement of the bone marrow were especially common among patients with IgM M components.

In leukemia (Table VI) a high prevalence (45%) of IgM M components was also noted; the components were found mainly in patients with chronic lymphocytic leukemia, who composed 74% of the group. The ratio of κ to λ

Table II—Diagnoses in Toronto and New York series of patients with M components

Diagnosis	No. (and %) of patients		
	New York ^a	Toronto (our series)	Total
Multiple myeloma	303 (37.6)	632 (50.9)	935 (45.7)
Macroglobulinemia	66 (8.2)	45 (3.6)	111 (5.4)
Cancer	128 (15.9)	180* (14.5)	308 (15.1)
Amyloidosis	70 (8.7)	31 (2.5)	101 (4.9)
Others†	239 (29.7)	354 (28.5)	593 (28.9)
Total	806 (100.1)	1242 (100.0)	2048 (100.0)

*Includes 72 with cancer, 62 with lymphoma and 46 with leukemia.

†Includes 53 patients with connective tissue disease.

Table III—Classification of malignant plasmacytic diseases by class of M component

Disease	No. (and %) of patients		
	Data of Zawadzki and Edwards ^a	Data of our series	Combined data
IgG myeloma	816	385	1201 (53.0)
IgA myeloma	369	122	491 (21.7)
Light-chain disease	171	106	277 (12.2)
Other myelomas	39	19	58 (2.6)
Macroglobulinemia	194	45	239 (10.5)
Total	1589	677	2266 (100.0)

Table IV—Prevalence of M components and Bence Jones proteinuria in multiple myeloma

Table I—Prevalence of 1255 serum M components according to class and type

Class and type of M component	No. (and %)
IgG	
κ	459 (36.6)
λ	273 (21.8)
IgA	
κ	102 (8.1)
λ	83 (6.6)
IgM	
κ	83 (6.6)
λ	42 (3.3)
Unidentified	39 (3.1)
BJP*	
κ	66 (5.3)
λ	57 (4.5)
IgD	
κ	1 (0.08)
λ	11 (0.9)
Biclonal†	16† (2.5)
Unidentified‡	7 (0.6)

*BJP = Bence Jones protein.

†Sixteen pairs or 32 M components (excluding cases with Bence Jones proteinemia in addition to whole-molecular M component).

‡Very small but definite spikes of γ mobility, probably IgG.

Class and type of M component	No. (and %) of patients	Urine	
		No. of samples examined	No. (and %) with Bence Jones protein
IgG			
κ	242	151	106 (70.2)
λ	143		
IgA			
κ	65	40	21 (52.5)
λ	57		
LCD			
κ	59	59	59 (100.0)
λ	47		
IgD			
κ	1	1	1
λ	11		
Biclonal	5		
IgM	2	2	1 (50.0)
Total	632 (100.0)	444	325 (73.2)

LCD = light-chain disease — i.e., multiple myeloma with Bence Jones protein in the serum as the only M component.

light chains in the leukemia group was 1.3:1. An increased, but smaller, prevalence (24%) of IgM M components was also noted in patients with cancer (Table VII). The overall ratio of κ to λ light chains in this group was 1.1:1. Of 48 patients with cancer the serum concentrations of immunoglobulins other than M component were greatly decreased in only 7, and in 6 others the concentration of only one immunoglobulin was low.

A different distribution of M components was observed in patients with primary generalized amyloidosis (Table VIII): in 50% of the patients Bence Jones protein was the only M component in the serum (so-called light-chain disease) and the ratio of κ to λ light chains was reversed — 1:2.1.

In connective tissue diseases (Table IX) the majority of M components (70%) were of the IgG class. The ratio of κ to λ light chains was 1.8:1. Bence Jones protein was detected in 41% of the urine samples examined.

The prevalence of M components in 301 patients with various benign diseases is summarized in Table X. The concentration of M components in the serum exceeded 1.0 g/dl in 58, 64 and 18% of patients with IgG, IgA and IgM M components, respectively. The ratio of κ to λ light chains was 1.8:1. In 28 patients in this group Bence Jones protein was detected in the urine; 2 had angioimmunoblastic lymphadenopathy, 1 had lichen myxedematosus, 1 had essential cryoglobulinemia, 3 had chronic, ill-defined anemia and the rest had conditions unrelated to plasmacytic dyscrasias, such as osteoarthritis or arteriosclerotic cardiovascular disease. All these patients were older than 45 years and most were older than 60

Table V—Prevalence of M components in Waldenström's macroglobulinemia and in lymphomatous diseases

Class and type of M component	No. of patients	
	Waldenström's macroglobulinemia (n = 45)	Lymphoma (n = 53) and Hodgkin's disease (n = 11)
IgG		
κ	—	17
λ	—	5
IgA		
κ	—	5
λ	—	2
IgM		
κ	30	16
λ	12	11
Unidentified	3	5
Biclonal	—	3*
Urine		
BJP	14	7
No BJP	10	9

*IgG(λ) + IgG(λ); IgA(κ) + IgM(κ); IgG(κ) + IgM(κ).

years. Among 197 of these patients the serum concentrations of two immunoglobulins other than M component were decreased in 6% and the concentration of one immunoglobulin was low in 21%; the other patients had normal or increased concentrations.

Discussion

The prevalence of M components in a general population over 25 years of age was found to be 0.9%.⁵ In that survey of 6995 persons all 64 with M components were examined and only 7 were found to have a malignant disease. Further clinical information was

obtained in 55 of the 64 individuals 5½ years later. Of the 16 who had died only 5 had had malignant diseases. No change in the serum concentration of M components was detected in the 39 survivors and malignant disease had not developed in any.⁶ Thus, in 91% with M components the condition was still benign after 5½ years.

Among 13 400 healthy young adults in another study the prevalence of M components was 0.15%.⁷ Of 20 individuals with M components only 4 had malignant diseases. Surveys of two large series of hospital patients (7200 and 5327 patients, respectively) showed the

Table VI—Prevalence of M components in leukemia*

Class and type of M component	CLL (n = 34)	AML (n = 4)	AMML (n = 3)	ABCL (n = 2)	ALL (n = 1)	AL (n = 1)	CML (n = 1)	Total (n = 46)
IgG								
κ	8	—	1	2	1†	—	—	12
λ	5	1	1	—	—	—	—	7
IgA								
κ	—	—	—	—	—	—	—	—
λ	2	—	—	—	—	—	—	2
IgM								
κ	7	1	—	—	—	1	—	9
λ	8	—	—	—	—	—	—	8
Unidentified	3	—	—	—	—	—	1	4
BJP	1 (κ)	—	—	—	—	—	—	1

Urine

BJP	8	2†	1†	—	—	—	—	11
No BJP	3	1	2	—	—	—	—	6

* Abbreviations: CLL = chronic lymphocytic leukemia; AML = acute myeloblastic leukemia; AMML = acute myelomonocytic leukemia; ABCL = acute blast cell leukemia; ALL = acute lymphoblastic leukemia; AL = aleukemic leukemia; CML = chronic myelogenous leukemia.

†Biclonal with IgG(λ).

‡No M components in serum.

Table VII—Prevalence of M components in cancer

Site or type of neoplasia	No. of patients	Class and type of M component							
		IgG		IgA		IgM		Unidentified	BJP
		κ	λ	κ	λ	κ	λ		
Breast	12	8	3	—	—	—	1	—	—
Metastatic cancer	11	2	3*	1	—	2	—	2	1 (λ)
Colon	10	4	2	1	2	1	—	—	—
Lung	9	2	2	—	2	2	—	1	—
Urinary bladder	4	—	2	—	1	—	—	1	—
Prostate	3	—	1	—	—	1	—	1	—
Malignant melanoma	3	2	—	—	—	1	—	—	—
Ovary	2	—	1	—	—	—	—	1	—
Skin, basal cell	2	—	1	1	—	—	—	—	—
Pancreas	2	1	—	1	—	—	—	—	—
Thyroid	2	1	1	—	—	—	—	—	—
Kidney	1	1†	—	—	—	—	—	—	—
Uterine cervix	1	—	1	—	—	—	—	—	—
Hepatoma	1	—	1	—	—	—	—	—	—
Tongue	1	—	1	—	—	—	—	—	—
Larynx	1	—	1	—	—	—	—	—	—
Kaposi's sarcoma	1	1	—	—	—	—	—	—	—
Stomach	1	1	—	—	—	—	—	—	—
Lip	1	1	—	—	—	—	—	—	—
Oropharynx	1	—	—	—	—	—	—	1	—
Gastric neurofibrosarcoma	1	—	—	—	—	—	1†	—	—
Seminoma	1	—	—	—	—	1	—	—	—
Neuroblastoma	1	—	1	—	—	—	—	—	—
Total	72	24	21	4	5	8	2	7	1

*One biclonal with IgA(λ).

†One biclonal with IgA(κ).

‡With cryoglobulin.

same prevalence of M components — 0.8%.⁸⁻¹⁰

It seems, therefore, that when an M component is detected incidentally, especially in a young individual, the chance that the condition is benign is high. The fact that in our series 50.9% of the patients had multiple myeloma and 18.1% had nonmyelomatous malignant diseases does not contradict this statement. Our series was composed mainly of hospital patients referred for special studies. A similar observation was made in other referral centres^{3,11-13} but, since the referral policy varied, the proportion of patients with benign conditions associated with M components varied too, ranging from 16.5¹³ to 53%.¹² In our series the prevalence of such benign conditions was 31%, identical to that reported by Isobe and Osserman.³ However, malignant disease is seen to develop in some patients with these benign conditions associated with M components if the follow-up period is sufficient.

Patients with multiple myeloma have made up 38 to 73% of large series of individuals with M components.^{3,12,13} The majority of M components in mul-

iple myeloma belong to the IgG class.¹¹ Approximately two thirds of M components have κ light chains, but the ratio of κ to λ light chains varies in different classes of M components and among various diseases. For example, in our patients with IgG myeloma 63% of M components had κ light chains, whereas the frequency in IgA myeloma was 53% and in IgD myeloma, 8%. M components with κ light chains predominated in Waldenström's macroglobulinemia, cancer, lymphoma, leukemia and connective tissue diseases. In contrast, M components with λ light chains predominated in primary generalized amyloidosis.

Comparison of diagnoses in our series with those in a similar series from New York³ (Table II) showed a lower proportion of multiple myeloma and a higher proportion of amyloidosis in the latter.

The distribution of various classes of M components in nonmyelomatous malignant diseases differed from that in multiple myeloma. In lymphoma and leukemia almost half the M components belonged to the IgM class. The proportion of IgM M components in patients with cancer and with connective tissue diseases was also higher (24 and 23%, respectively) than the proportion in the whole series (13.0%). A much higher prevalence of Bence Jones proteinemia was observed in primary generalized amyloidosis (48%) than in multiple myeloma (17%). The prevalence of Bence Jones proteinemia in nonmyelomatous neoplastic diseases was very low. Patients who could not be classified into any of the groups of diseases in which M components are usually detected were classified as "others" or as having "unclassified benign" conditions. In this group the proportion of IgM M components was low (6.4%) and no Bence Jones proteinemia was detected. In approximately half of these patients the serum

Table VIII—Prevalence of M components in primary generalized amyloidosis

Class and type of M component	No. of patients (n = 31)
IgG	
κ	3
λ	8*
IgA	
κ	1
λ	3
IgM	
λ	1
BJP	
κ	6
λ	9
Urine	
BJP	24
No BJP	7

*Four serum samples also contained BJP(λ).

Table IX—Prevalence of M components in connective tissue diseases

Disease	No. of patients	Class and type of M component								Urine	
		IgG		IgA		IgM		Un-identified	BJP	No BJP	
		κ	λ	κ	λ	κ	λ				
Rheumatoid arthritis	28	13	8	2	1	2	1	1	11	9	
Systemic lupus erythematosus	4	3	—	—	—	—	—	1	0	2	
Scleroderma	3	2	1	—	—	—	—	—	—	—	
Felty's syndrome	3	—	1	—	—	1	1	—	—	—	
Dermatomyositis	2	—	—	—	—	2*	—	—	1	1	
Wegener's granulomatosis	1	—	—	—	—	—	1	—	0	1	
Sjögren's syndrome	1	—	—	—	—	—	—	1	0	1	
Peetoom-Meltzer syndrome	1	—	—	—	—	1*	—	—	0	1	
Collagen disease, unclassified	6	4†	2	—	—	—	—	—	1	2	
Seronegative arthritis	4	3	—	—	1	—	—	—	0	2	
Total	53	25	12	2	2	6	3	3	13	19	

*With cryoglobulins.

†One biconal with IgG(λ).

HALOG CREAM

Halcinonide 0.1%

Halog Cream (halcinonide, 0.1%) is intended for use as an anti-inflammatory agent for topical application. Halog Cream, 0.1%, provides 0.1% halcinonide, in a specially formulated water-washable base consisting of glyceryl monostearate, cetyl alcohol, myristyl stearate, isopropyl palmitate, polysorbate 60, and propylene glycol.

ACTION: Halog Cream, 0.1%, produces significant or complete therapeutic responses in patients with acute or chronic corticosteroid-responsive dermatoses.

INDICATIONS: Halog Cream, 0.1%, is indicated for topical application for relief of the many acute or chronic corticosteroid-responsive dermatoses.

CONTRAINDICATIONS: Tuberculous, fungal and most viral lesions of the skin (including herpes simplex, vaccinia and varicella).

Halog Cream is not intended for use in the eye nor in the external auditory canal of patients with perforated eardrums.

WARNINGS: Systemic side effects may occur and must be kept in mind particularly during use over large areas or for an extended period of time. Occasionally, symptoms of steroid withdrawal may develop when the medication is stopped after prolonged use.

Pregnancy: Safety has not been established. Potential benefit should be weighed against possible hazard.

PRECAUTIONS: If local infection (other than those cited in CONTRAINDICATIONS) exists, suitable concomitant antimicrobial therapy should be administered. If a favourable response does not occur promptly, application of the corticosteroid should be discontinued until the infection is adequately controlled by appropriate measures.

If local irritation or sensitization develops, halcinonide cream should be discontinued.

Occlusive Dressing Technique: The use of occlusive dressings increases the percutaneous absorption of corticosteroids and the possibility of systemic effects. For patients with extensive lesions it may be preferable to use a sequential approach. The patient should be kept under close observation during prolonged occlusive therapy.

Thermal homeostasis may be impaired if large areas of the body are occluded.

Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive.

If infection develops, discontinue the use of the occlusive dressings and institute appropriate antimicrobial therapy.

ADVERSE REACTIONS: Significant local irritation is uncommon; a transient burning sensation may occur in some patients. The use of corticosteroids under occlusive dressings is known to produce milium, folliculitis, pyoderma, or localized cutaneous atrophy; striae occasionally develop. Erythema, dryness, itching and change in skin pigmentation have been reported with topical steroids.

SYMPTOMS AND TREATMENT OF OVERDOSAGE: Mild, reversible suppression of adrenal function, ecchymoses of the skin, peptic ulceration, hypertension, aggravation of infection, hirsutism, acne, edema and muscle weakness due to protein depletion are all toxic symptoms of corticosteroids. Animal studies suggest that overdosage may result in swollen breasts or lactation. Treatment is symptomatic; corticosteroid administration should be discontinued.

DOSAGE AND ADMINISTRATION: Usual adult dosage range: 2 to 3 applications daily.

Occlusive Dressing Technique: Gently rub a small amount of the Halog Cream, 0.1%, into the lesion until the cream disappears. Then re-apply the cream, leaving a thin coating on the lesion and cover with a pliable non-porous film. Good results have been obtained by applying Halog Cream, 0.1%, under occlusion in the evening and reapplying Halog Cream, 0.1%, without occlusion in the morning (i.e. — 12-hour occlusion). Reapplication of the preparation is essential at each dressing change.

DOSAGE FORMS: Halog Cream is supplied as cream formulation containing 0.1% halcinonide, in tubes of 15, 30 and 60 g.

STORAGE: Store at room temperature. Avoid freezing. Avoid prolonged storage at temperatures exceeding 30°C.

Product monograph available to physicians and pharmacists on request.

References: 1. Data on file, Squibb Institute of Medical Research. 2. Sudilovsky A, Clewe TH: *J Clin Pharmacol* 15:779-784, 1975. 3. Clark RF, Clement ER: *Arch Dermatol* 111:731-733, 1975.



E. R. SQUIBB & SONS LTD.
2365 COTE DE LIESSE, MONTREAL, QUE.
H4N 2M7

VELOSEF 250 CAPSULES

VELOSEF 500 CAPSULES

Cephadrine Capsules

VELOSEF 125 FOR ORAL SUSPENSION

VELOSEF 250 FOR ORAL SUSPENSION

Cephadrine for Oral Suspension

VELOSEF FOR INJECTION, 500 mg and 1 g

Cephadrine for Injection

ACTION: Cephadrine is a semi-synthetic, cephalosporin antibiotic exhibiting bactericidal activity through inhibition of cell-wall synthesis.

INDICATIONS: Infections in the respiratory and genitourinary tracts, and in the skin and soft tissues, due to susceptible organisms.

Sensitivity tests should be performed; therapy may be instituted before receiving the results.

CONTRAINDICATIONS: Hypersensitivity to the cephalosporin group of antibiotics.

WARNINGS: There is evidence of partial cross-allergenicity between the penicillins and the cephalosporins. Therefore, cephadrine should be used with caution in patients with known hypersensitivity to penicillins.

Antibiotics, including cephadrine, should be used cautiously and only when absolutely necessary in patients with a history of allergies, particularly to drugs.

Usage during pregnancy and lactation:

Safety for use of this product during pregnancy has not been established. Cephadrine is secreted in breast milk.

PRECAUTIONS: Patients should be observed carefully during therapy. Allergic reactions require discontinuation of VELOSEF and appropriate treatment.

Prolonged use of VELOSEF may result in overgrowth of non-susceptible organisms; appropriate measures should be instituted. During long-term therapy, hematological, renal and hepatic functions should be monitored periodically. Patients with known or suspected renal impairment should be observed carefully since cephadrine may accumulate in the serum and tissues unless dosage is suitably reduced. See DOSAGE AND ADMINISTRATION section.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy; e.g., the incision and drainage of abscesses. After treatment with cephalosporins, a false-positive reaction for glucose in the urine may occur, but not with enzyme-based tests. A false-positive Coombs' test has also been reported. VELOSEF for Injection is not compatible with Lactated Ringer's Solution or other calcium-containing infusion fluids.

ADVERSE REACTIONS: Usually limited to gastrointestinal disturbances and occasional hypersensitivity, but may include hematological and hepatobiliary disturbances, as well as elevated BUN, LDH or serum creatinine; superinfection; vaginitis and joint pains. Thrombophlebitis following I.V. injection and sterile abscesses after I.M. injection have occurred.

Only occasionally severe enough to warrant cessation of therapy

DOSAGE AND ADMINISTRATION: The presence of food in the gastrointestinal tract delays the absorption and reduces the peak level but does not affect the total amount of cephadrine absorbed. VELOSEF Capsules and VELOSEF for Oral Suspension

Adults: Respiratory tract infections: 250 mg, q6h. Pneumococcal lobar pneumonia: 500 mg, q6h.

Genitourinary tract infections: 500 mg, q6h. Prolonged therapy is advisable for the treatment of prostatitis and epididymitis.

Children: 25 to 50 mg/kg/day, divided into four equally spaced doses, e.g.:

VELOSEF for Oral Suspension

Child's Weight	125 mg/5 ml	250 mg/5 ml
10 kg (22 lbs)	½ to 1 tsp, q6h	—
20 kg (44 lbs)	1 to 2 tsp, q6h	½ to 1 tsp, q6h
40 kg (88 lbs)	2 to 4 tsp, q6h	1 to 2 tsp, q6h

Smaller doses than those indicated above should not be used. For otitis media due to *H. influenzae*, doses from 75 to 100 mg/kg/day are recommended.

VELOSEF for Injection: For use in serious and life-threatening infections or where oral therapy is not possible. Average adult daily dose is 2 - 4 g, depending on the infection. In children, a daily dose of 50 - 100 mg/kg is recommended.

All patients: all formulations:

Larger doses (up to 1 g q6h in adults or up to 25 mg/kg q6h in children) may be given for severe or chronic infections; maximum daily dose should not exceed 4 g. Therapy should be continued for a minimum of 48 to 72 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. In infections caused by hemolytic streptococci, a minimum 10-day-treatment period is recommended. Stubborn infections may require treatment for several weeks with frequent bacteriological and clinical appraisal.

A modified dosage schedule in patients with decreased renal function is necessary. Each patient should be considered individually; the following schedule is recommended as a guideline. Initial loading dose: 750 mg. Maintenance dose: 500 mg at the time intervals listed below:

Creatinine Clearance (ml/min/1.73m ²)	Time Interval
> 20 ml/min	6 - 12 hours
15-19 ml/min	12 - 24 hours
10-14 ml/min	24 - 40 hours
5-9 ml/min	40 - 50 hours
< 5 ml/min	50 - 70 hours

DOSAGE FORMS: Capsules of 250 mg and 500 mg in bottles of 50, and bottles of VELOSEF 125 and 250 for Oral Suspension which, after reconstitution, provide 100 ml of pleasantly flavoured suspension containing 25 mg/ml and 50 mg/ml respectively.

VELOSEF for Injection is provided as a sterile powder for reconstitution in vials containing 500 mg or 1 g. Consult Product Monograph for reconstitution procedure.

Product Monograph available to physicians and pharmacists on request.

E. R. SQUIBB & SONS LTD.
2365 COTE DE LIESSE, MONTREAL, QUE.
H4N 2M7

concentration of M components exceeded 1.0 g/dl at the time of detection, and in many the concentration exceeded 2.0 g/dl.

Among the patients with cancer and M components, carcinoma of the breast, colon and lung, and generalized metastatic cancer with no evident primary focus were the most frequent types of cancer, affecting 58% of the whole group. In the series of Isobe and Osserman³ the commonest tumours associated with M components were adenocarcinoma or adenomatous polyp of the rectosigmoid colon, and prostatic and breast cancers, accounting for more than two thirds of the group. In another series stomach and skin cancer were frequently observed.¹⁴

Bence Jones proteinuria was found in more than 70% of the patients with multiple myeloma, and in other diseases the prevalence varied from 36 to 77%; the overall prevalence was 66%. Therefore, the finding of M component or Bence Jones proteinuria, or both, cannot distinguish a neoplastic process from a benign condition. Nor is the serum concentration of M components helpful, although in multiple myeloma and Waldenström's macroglobulinemia the concentration is usually higher than in other diseases. The concentrations of immunoglobulins other than M components are usually decreased in multiple myeloma and macroglobulinemia. Low concentrations of immunoglobulins were observed only rarely in the groups of patients with cancer and unclassified benign disorders. No depression of immunoglobulin production was noted in patients with connective tissue disorders and M components.

Table X—Prevalence of M components according to class and type in unclassified benign conditions*

Class and type of M component	No. (and %) of patients (n = 301)
IgG	
κ	141 (47.0)
λ	78 (25.5)
IgA	
κ	25 (8.4)
λ	12 (4.0)
IgM	
κ	14 (4.7)
λ	5 (1.7)
Unidentified	15 (5.0)
Biclonal†	4 (1.3)
Unidentified	7 (2.3)
Urine	
BJP	28 (36.0)
No BJP	48 (64.0)

* Chronic liver disease (18), peripheral neuropathy (5), various anemias (12), idiopathic cryoglobulinemia (3), chronic cold agglutinin disease (3), myelofibrosis (3), lichen myxedematosus (1), angioimmunoblastic lymphadenopathy (2) and others (254).
† IgG(κ) + IgG(λ); IgG(λ) + IgG(λ); IgA(κ) + IgG(κ); IgG(λ) + IgM(λ).

It is not clear whether suppression of immunoglobulin production is definite evidence of a malignant process. It seems, however, that patients with M components and low concentrations of immunoglobulins should be checked repeatedly for malignant disease, and the finding of an M component always warrants extensive investigation. A diagnosis of "benign" M components should be made by exclusion only; malignant disease may develop in patients with these seemingly benign conditions. Therefore, all patients with M components should be followed up for long periods. Transient appearance of M components has been described,¹⁵ and we have observed this in a few patients.

We thank all our colleagues who sent serum and urine samples for investigation, provided clinical information or referred their patients to us. We acknowledge especially the cooperation of Drs. D.E. Bergsagel, R. Hasselback, J.H. Crookston, J.S. Senn, J.G. Scott, D.H. Cowan, A.H. Squires, G.J. Kutas, J.G. Watt, D.M.C. Sutton and I. Rother, and also Mrs. R. Nesseth for typing the manuscript.

This work was supported by a grant-in-aid from the Ontario Cancer Treatment and Research Foundation.

References

- PRUZANSKI W, WATT JG: Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature. *Ann Intern Med* 77: 853, 1972
- MACKECHNIE HL, OGRYZLO MA, PRUZANSKI W: Heterogeneity of IgM/IgG cryocloplexes: immunological-clinical correlation. *J Rheumatol* 2: 225, 1975
- ISOBE T, OSSERMAN EF: Pathologic conditions associated with plasma cell dyscrasia. A study of 806 cases. *Ann NY Acad Sci* 190: 507, 1971
- ZAWADZKI ZA, EDWARDS GA: M-components in immunoproliferative disorders. Electrophoretic and immunologic analysis of 200 cases. *Am J Clin Pathol* 48: 418, 1967
- AXELSSON U, BACHMANN R, HÄLLÉN J: Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. *Acta Med Scand* 179: 235, 1966
- AXELSSON U, HÄLLÉN J: A population study on monoclonal gammopathy. Follow-up after 5 and one-half years on 64 subjects detected by electrophoresis of 6995 sera. *Acta Med Scand* 191: 111, 1972
- FINE JM, LAMBIN P, LEROUX P: Frequency of monoclonal gammopathy ('M components') in 13,400 sera from blood donors. *Vox Sang* 23: 336, 1972
- HOBBS JR: Disturbances of the immunoglobulins. *Sci Basis Med Annu Rev* 1966, pp 106-27
- Idem: Paraproteins, benign or malignant? *Br Med J* 3: 699, 1967
- TAKATSUKI K: Personal communication, 1971
- OBERDORFER A, SCHNAUFFER K, LANGE HJ, et al: Zur Verteilung von Paraproteinämien nach Geschlecht und Alter der Patienten, Paraprotein-Klassen, -Subklassen und -Leichtketten-Typen. *Z Klin Chem Klin Biochem* 11: 51, 1973
- STREIFF F, HUMBERT JC, BERTRAND F, et al: Fréquence des gammopathies monoclonales isolées. Confrontation bioclinique à propos de 394 cas d'immunoglobulines pathologiques. *Nouv Rev Fr Hematol* 11: 636, 1971
- DUGUE M, ROUSSELET F, KAHN MF, et al: Etudes biologiques sur 559 cas de paraprotéinémies. *Clin Chim Acta* 33: 75, 1971
- BACHMANN R: Studies on serum immunoglobulins with special reference to pathological proteins (M-components). *Acta Universitatis Lund Sectio II*, no 10, 1966
- DANON F, SELIGMANN M: Transient human monoclonal immunoglobulins. *Scand J Immunol* 1: 323, 1972